FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2071661402> ?p ?o ?g. }

• W2071661402 endingPage "115" @default.
• W2071661402 startingPage "111" @default.
• W2071661402 abstract "Randomized controlled trials indicate that sirolimus-eluting stents (SES) reduce the rates of restenosis and need for subsequent revascularization procedures, but patients enrolled in randomized trials represent a highly selected population. This study examined the performance of SES in a 'real world' setting by comparing the outcomes of trial-eligible versus ineligible patients undergoing percutaneous coronary intervention.From the US commercial introduction of SES in April 2003 until December 2003, all patients that received an SES at our institution were followed in a prospective registry (n=838). For the purpose of this analysis, the registry population was divided into two groups based on the inclusion and exclusion criteria of the stenosis in a native coronary artery (SIRIUS) trial. The primary endpoint of the study was the rate of target lesion revascularization (TLR) at follow-up. Secondary endpoints included major adverse cardiac events (MACE) such as cardiac death, myocardial infarction, and target vessel revascularization. Clinical follow-up was complete for 92% of patients with a median duration of 14.2 months.Overall, 296 patients (35.3%) met entry criteria for the SIRIUS trial and thus comprised the SIRIUS eligible group. Patients in the SIRIUS ineligible group (n=542) were more likely to have chronic kidney disease and earlier bypass surgery and had longer mean stent length. At 1 year, TLR occurred in 3.0% of the SIRIUS eligible population and in 9.2% of the SIRIUS ineligible group (P=0.001). The secondary endpoint of cumulative MACE occurred in 6.6% of the SIRIUS eligible versus in 17.7% of the SIRIUS ineligible population (P<0.001). Two patients (0.4%) in the SIRIUS ineligible group had a late stent thrombosis on days 39 and 99, respectively, versus none in the SIRIUS eligible group.Among 'real world' patients treated with SES, the incidence of TLR and MACE at 1 year was substantially greater among SIRIUS ineligible patients compared with SIRIUS eligible patients. These findings confirm that pivotal clinical trials of drug-eluting stents tend to enroll low-risk patients and that the estimated rates of TLR and MACE derived from such trials may not reflect subsequent outcomes with unrestricted clinical use." @default.
• W2071661402 created "2016-06-24" @default.
• W2071661402 creator A5017859804 @default.
• W2071661402 creator A5023500010 @default.
• W2071661402 creator A5024220356 @default.
• W2071661402 creator A5057352435 @default.
• W2071661402 creator A5058875978 @default.
• W2071661402 creator A5060743527 @default.
• W2071661402 creator A5065480866 @default.
• W2071661402 creator A5065696361 @default.
• W2071661402 creator A5078870461 @default.
• W2071661402 creator A5087336103 @default.
• W2071661402 date "2008-03-01" @default.
• W2071661402 modified "2023-09-26" @default.
• W2071661402 title "Differential outcomes after sirolimus-eluting stent implantation: comparing on-label versus off-label patients in the ‘real world’" @default.
• W2071661402 cites W2062782229 @default.
• W2071661402 cites W2079818105 @default.
• W2071661402 cites W2083630382 @default.
• W2071661402 cites W2112145710 @default.
• W2071661402 cites W2132124166 @default.
• W2071661402 cites W2135866603 @default.
• W2071661402 cites W2139998313 @default.
• W2071661402 cites W2146665526 @default.
• W2071661402 cites W81592273 @default.
• W2071661402 doi "https://doi.org/10.1097/mca.0b013e3282f34220" @default.
• W2071661402 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/18300748" @default.
• W2071661402 hasPublicationYear "2008" @default.
• W2071661402 type Work @default.
• W2071661402 sameAs 2071661402 @default.
• W2071661402 citedByCount "14" @default.
• W2071661402 countsByYear W20716614022012 @default.
• W2071661402 countsByYear W20716614022013 @default.
• W2071661402 countsByYear W20716614022014 @default.
• W2071661402 countsByYear W20716614022017 @default.
• W2071661402 crossrefType "journal-article" @default.
• W2071661402 hasAuthorship W2071661402A5017859804 @default.
• W2071661402 hasAuthorship W2071661402A5023500010 @default.
• W2071661402 hasAuthorship W2071661402A5024220356 @default.
• W2071661402 hasAuthorship W2071661402A5057352435 @default.
• W2071661402 hasAuthorship W2071661402A5058875978 @default.
• W2071661402 hasAuthorship W2071661402A5060743527 @default.
• W2071661402 hasAuthorship W2071661402A5065480866 @default.
• W2071661402 hasAuthorship W2071661402A5065696361 @default.
• W2071661402 hasAuthorship W2071661402A5078870461 @default.
• W2071661402 hasAuthorship W2071661402A5087336103 @default.
• W2071661402 hasConcept C126322002 @default.
• W2071661402 hasConcept C141071460 @default.
• W2071661402 hasConcept C164705383 @default.
• W2071661402 hasConcept C168563851 @default.
• W2071661402 hasConcept C203092338 @default.
• W2071661402 hasConcept C207103383 @default.
• W2071661402 hasConcept C2778213512 @default.
• W2071661402 hasConcept C2778283817 @default.
• W2071661402 hasConcept C2778583881 @default.
• W2071661402 hasConcept C2779464278 @default.
• W2071661402 hasConcept C2780400711 @default.
• W2071661402 hasConcept C2780739214 @default.
• W2071661402 hasConcept C2908647359 @default.
• W2071661402 hasConcept C44249647 @default.
• W2071661402 hasConcept C500558357 @default.
• W2071661402 hasConcept C71924100 @default.
• W2071661402 hasConcept C99454951 @default.
• W2071661402 hasConceptScore W2071661402C126322002 @default.
• W2071661402 hasConceptScore W2071661402C141071460 @default.
• W2071661402 hasConceptScore W2071661402C164705383 @default.
• W2071661402 hasConceptScore W2071661402C168563851 @default.
• W2071661402 hasConceptScore W2071661402C203092338 @default.
• W2071661402 hasConceptScore W2071661402C207103383 @default.
• W2071661402 hasConceptScore W2071661402C2778213512 @default.
• W2071661402 hasConceptScore W2071661402C2778283817 @default.
• W2071661402 hasConceptScore W2071661402C2778583881 @default.
• W2071661402 hasConceptScore W2071661402C2779464278 @default.
• W2071661402 hasConceptScore W2071661402C2780400711 @default.
• W2071661402 hasConceptScore W2071661402C2780739214 @default.
• W2071661402 hasConceptScore W2071661402C2908647359 @default.
• W2071661402 hasConceptScore W2071661402C44249647 @default.
• W2071661402 hasConceptScore W2071661402C500558357 @default.
• W2071661402 hasConceptScore W2071661402C71924100 @default.
• W2071661402 hasConceptScore W2071661402C99454951 @default.
• W2071661402 hasIssue "2" @default.
• W2071661402 hasLocation W20716614021 @default.
• W2071661402 hasLocation W20716614022 @default.
• W2071661402 hasOpenAccess W2071661402 @default.
• W2071661402 hasPrimaryLocation W20716614021 @default.
• W2071661402 hasRelatedWork W2020050573 @default.
• W2071661402 hasRelatedWork W2089715561 @default.
• W2071661402 hasRelatedWork W2100465349 @default.
• W2071661402 hasRelatedWork W2399063111 @default.
• W2071661402 hasRelatedWork W2598466201 @default.
• W2071661402 hasRelatedWork W2756842118 @default.
• W2071661402 hasRelatedWork W2885951725 @default.
• W2071661402 hasRelatedWork W2902149400 @default.
• W2071661402 hasRelatedWork W3161548046 @default.
• W2071661402 hasRelatedWork W416619884 @default.
• W2071661402 hasVolume "19" @default.
• W2071661402 isParatext "false" @default.
• W2071661402 isRetracted "false" @default.
• W2071661402 magId "2071661402" @default.

• next